In a world facing enormous health challenges and an industry undergoing profound disruption, we are actively helping businesses, governments and individuals through the transition to a new health economy. PwC’s purpose is "to build trust in society and solve important problems". Our Team at PwC demonstrate a commitment and passion to this purpose every day in the work we deliver for and with the health industries.
PwC has a strong Pharma team with relevant knowledge and experience in China to provide our clients with practical solutions. Our approach is to bring clients a multidisciplinary set of capabilities tailored to their unique business needs. These capabilities permit us to leverage deep resources and experience across our practice in pharmaceutical industry. Our Assurance and Tax practices provide unique financial, regulatory and compliance skill sets; our Consulting Services cover the full spectrum of strategic planning and operational concerns; and our Deals Services help clients through each stage of the deal process, from M&A strategy to post-acquisition integration.
A look at current financial reporting issues
Drop in value and volume of deals in the M&A market of China pharmaceuticals and medical devices sector.
M&A in China’s medical device sector.
New health reform has been rolled out to accommodate the rising of residents income level and healthcare awareness.
In this year's survey, 89 pharmaceuticals & life sciences CEOs from 37 countries share their views on the impact of globalisation, technological change, talent and trust.
A new direction for real estate industry transformation
China has listed hospital information system construction as an important part of hospital reform since 2011, and HRP (Hospital Resource Planning) system can help hospital implement its management strategy